Funding for this research was provided by:
Veritas Pharma Inc
Received: 28 March 2019
Accepted: 22 April 2020
First Online: 11 May 2020
: All studies were performed with the approval of the University of British Columbia Animal Care Committee and were conducted and reported according to ARRIVE guidelines.
: Not applicable.
: Cannevert Therapeutics is strictly a research organization and is a wholly owned subsidiary of Veritas Pharma. Cannevert Therapeutics does not produce any products for sale or generate revenue. A Material Transfer Agreement was signed with CanniMed Ltd. to use their materials for not-for-profit research purposes. Neither CanniMed nor Veritas Pharma had input on any part of the study, decision to publish, or approval of the manuscript.